VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II

Join Volition’s webinar where chief commercial officer Gael Forterre and intensive care specialist and haematology key opinion leader Dr Andrew Retter will cover:

• an introduction to Volition;
• disease background, patient case studies and the challenges in diagnosing, treating and monitoring sepsis;
• the connection between NETosis and sepsis;
• the role of Nu.Q® NETs and its clinical evidence and ongoing clinical study programme; and
• Volition’s commercial strategy.

Chairing the panel and Q&A will be Soo Romanoff, managing director of healthcare at Edison Group.

Event details

Date: 13 February 2024

Time: 10.30am (US ET)/3.30pm (GMT)/4.30pm (CET)

Register here

For more information on VolitionRx, please read the latest updates on Edison’s website and visit the company’s website.

About VolitionRx

VolitionRx is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition’s research and development activities are centred in Belgium, with an innovation laboratory and office in the US and additional offices in London and Singapore.